Pure Global AI
NCT06364150Not yet recruiting

Therapeutic Use of Angiopoietin-Primed Autologous Peripheral Blood Stem Cell in Myocardial Infarction

Seoul National HospitalPhase 3ClinicalTrials.govbiological
Verified
Study focus
Disease/Condition
Acute Myocardial Infarction
Drug/Device/Intervention
Autologous Peripheral Blood Stem Cell injection
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Seoul National Hospital
Timeline & enrollment
Phase
Phase 3
Start date
May 01, 2024
End date
Aug 01, 2026
Enrollment
30 participants
Primary outcome

Left ventricular systolic function

Summary

This study will evaluate the efficacy and safety of Therapeutic Use of Autologous-Primed
 Autologous Peripheral Blood Stem Cell Treatment for Myocardial Regeneration in Acute
 Myocardial Infarction.

ICD-10 classifications
Acute myocardial infarctionAcute myocardial infarction, unspecifiedAcute subendocardial myocardial infarctionCertain current complications following acute myocardial infarctionOther current complications following acute myocardial infarction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06364150
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06364150 through Pure Global AI's free database. This Phase 3 trial is sponsored by Seoul National Hospital and is currently Not yet recruiting. The study focuses on Acute Myocardial Infarction. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.